AGIO vs. SNDX, SDGR, CPRX, GPCR, GERN, NAMS, AMRX, SUPN, AVDL, and HRMY
Should you be buying Agios Pharmaceuticals stock or one of its competitors? The main competitors of Agios Pharmaceuticals include Syndax Pharmaceuticals (SNDX), Schrödinger (SDGR), Catalyst Pharmaceuticals (CPRX), Structure Therapeutics (GPCR), Geron (GERN), NewAmsterdam Pharma (NAMS), Amneal Pharmaceuticals (AMRX), Supernus Pharmaceuticals (SUPN), Avadel Pharmaceuticals (AVDL), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical preparations" industry.
Syndax Pharmaceuticals (NASDAQ:SNDX) and Agios Pharmaceuticals (NASDAQ:AGIO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, community ranking, analyst recommendations, valuation and institutional ownership.
Agios Pharmaceuticals received 115 more outperform votes than Syndax Pharmaceuticals when rated by MarketBeat users. Likewise, 67.90% of users gave Agios Pharmaceuticals an outperform vote while only 64.48% of users gave Syndax Pharmaceuticals an outperform vote.
Syndax Pharmaceuticals has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -1,312.64%. Syndax Pharmaceuticals' return on equity of -38.08% beat Agios Pharmaceuticals' return on equity.
Syndax Pharmaceuticals presently has a consensus price target of $34.42, suggesting a potential upside of 67.31%. Agios Pharmaceuticals has a consensus price target of $33.50, suggesting a potential upside of 5.78%. Given Agios Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Syndax Pharmaceuticals is more favorable than Agios Pharmaceuticals.
Syndax Pharmaceuticals has higher revenue and earnings than Agios Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Syndax Pharmaceuticals has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.
In the previous week, Agios Pharmaceuticals had 1 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 2 mentions for Agios Pharmaceuticals and 1 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.22 beat Agios Pharmaceuticals' score of -0.10 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media.
Summary
Syndax Pharmaceuticals and Agios Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Agios Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Agios Pharmaceuticals Competitors List
Related Companies and Tools
